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A  variant of the B16 melanoma, clone C8471,  which  is nontumorigenic in immu- 
nocompetent mice, is capable of immunizing such mice against the parental, tumor- 
igenic  clone  B~59  (1,  2).  Clone  B559  is  not  immunogenic  and  does  not  induce 
concomitant tumor immunity (3). The immunogenic Ca471  variant was derived from 
B559  cells  by  continuous  growth  in  the  thymidine  analog,  5-bromodeoxyuridine 
(BrdUrd). 1 C3471  cells have undergone numerous phenotypic changes, including loss 
of tumorigenicity, pigmentation and plasminogen activator activity, as well as induc- 
tion  of  endogenous  retrovirus  (1,  4-6).  Other  investigators  have  also  produced 
immunogenic alterations of tumor cells by xenogenization with viruses (7-9), haptens 
(10,  11), mutagens  (12-15), and with antineoplastic drugs  (16-19). 
The inability of Ca471  cells to form  tumors reflects alteration(s) in interactions of 
these cells with the host's immune system, rather than an intrinsic loss of tumorigenic 
potential  of  C3471  cells  (20).  Immunocompetent  mice  mount  an  inflammatory 
response to C~471  cells within 24 h  after inoculation, and inhibit tumor formation by 
these cells (2, 21). Mice immunologically compromised by treatment with anti-mouse 
thymocyte serum  (ATS) or X  irradiation support tumor formation by Ca471  cells. 
In  the experiments reported here,  we have  mixed B559  cells with  peritoneal cells 
from  C3471  cell-immunized  mice  and  inoculated  the  mixtures  into  normal  and 
immunosuppressed mice (Winn-type assay) to analyze leukocyte populations respon- 
sible for immunity  to  B559  melanomas.  Our  results show  that  normal  mice do not 
develop  tumors  when  inoculated  with  a  mixture  of B559  cells and  peritoneal cells 
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from Ca471  cell-immunized mice, and that  a  high  percentage of these  mice retain 
long-lasting immunity to B559  cells. Thy-l.2  + peritoneal lymphocytes, or peritoneal 
macrophages  from  C3471  cell-immunized mice  each  protect  normal  mice  against 
melanoma formation when coinoculated with B559  cells. Thy-l.2  + lymphoeytes are 
required for both the generation and maintenance of tumoricidal macrophages in this 
system.  Significantly, tumoricidal  macrophages  from  C3471-immune mice  do  not 
protect antithymocyte serum treated recipient mice against B559 melanomas, indicat- 
ing that recipient thymus-dependent leukocytes are required to effect tumor eradica- 
tion. 
Materials and Methods 
Cells.  The derivation and maintenance of the melanotic tumorigenic B559 clone and the 
amelanotic,  nontumorigenic C3471 subclone  of  the  B16  melanoma have  been  described 
previously (6,  22).  Briefly,  cells  were  maintained in monolayer culture in Eagle's minimal 
essential medium (MEM) (Grand Island Biological Co., Grand Island, NY) supplemented with 
7.5% heat-inactivated fetal bovine serum (FBS) (M. A. Bioproducts, Walkersville, MD), 50/~g/ 
ml gentamycin (Schering Corp., Kenilworth, N  J), 50 ~g/ml aureomycin (Lederle Laboratories, 
Wayne, N  J), and 2.5/~g/ml fungizone (E. R.  Squibb & Sons, Inc., Princeton, N  J).  Cultures 
were incubated at 37°C in a humidified atmosphere containing 5% CO2. Cells of the Ca471 
subclone were grown continuously  in the presence of 1/~g/ml BrdUrd added to the maintenance 
medium. Semiconfluent monolayers were  dispersed using 0.0125% trypsin (Worthington Bio- 
chemical Corp., Freehold, N  J) with 2.6 mM EDTA. Total cell counts were determined with a 
Coulter counter and cell viability measured by trypan blue dye exclusion using a hemocytom- 
eter. Cells were checked periodically for mycoplasma using the Hoechst stain method (23); no 
mycoplasma were detected. 
Mice.  Female C57BL/6 mice, 5-7 wk of age, were obtained from the Mammalian Genetics 
Animal Production Section, Division of Cancer Treatment, National Cancer Institute at the 
Charles River Breeding Laboratories, Inc., Wilmington,  MA. 
Immunization.  C~471 cells used for  immunizing mice were  dispersed with trypsin, washed 
with serum-free MEM, and resuspended at 5 X  106 viable cells/ml MEM for inoculation. All 
mice used as donors of immune leukocytes for Winn assays were immunized by three intraper- 
itoneal inoculations of 106 viable cells at weekly intervals. 
To determine the effect  of immunization route on the capacity of the animal to reject a 
tumor challenge, a similar immunization schedule was followed  using subcutaneous injection 
of C3471 cells into the flank, followed by inoculation of 2 x  l0  s viable Ba59 cells (the minimal 
number required to yield tumors in  100% of mice injected) 7 d  after the last immunization, 
either intraperitoneally  or subcutaneously, into the opposite flank. Mice receiving subcutaneous 
challenge with Bs59 cells were monitored for tumor formation by examination  of the inoculation 
site for palpable melanoma nodules. Tumor development in the peritoneal cavity was monitored 
initially by  swelling of  the  abdomen,  and  confirmed  by  dissection  40  d  after  challenge. 
Intraperitoneal B559 tumors  are  easily visualized macroscopically as  pigmented masses  or 
extensive "peppering" of the mesentery. 
Irradiation.  Mice  were  exposed  to  650  rad  from  a  2,400  Ci  caesium source  gamma cell 
(located at  Memorial Sloan-Kettering Cancer Center, New York),  and were  maintained in 
sterile bedding and provided with sterile drinking water acidified to pH 2.0 with 1 N HC1. 
In  Vivo Depletion  of T  Lymphocytes.  Naive or Ca471 cell-immunized mice were  inoculated 
intraperitoneally with 0.2 ml rabbit ATS (M. A. Bioproducts) on days 6, 5, 3, 2, and I before 
use in an experiment. On day 0, mice were either inoculated with 2 X  10  ~ B559 tumor cells, 
inoculated with mixtures of peritoneal cells and B559 cells for Winn assays, or killed for harvest 
of peritoneal exudate cells (PEC). Wright-Giemsa staining of cytocentrifuged PEC from ATS- 
treated Ca471-immunized mice revealed 65% macrophages, 2% lymphoeytes, 16% neutrophils, 
17% eosinophils, and 0.5% mast cells. 
PEC.  PEC  were  harvested  by  lavage of the  peritoneal cavities of nai've  or  Ca471 cell- 
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according to a modification of the procedures of Cohn and Benson (24) as described by Michl 
et al.  (25). Immune PEC were collected 7 d after the last inoculation of C3471 ceils. Lysis of 
contaminating  erythrocytes was done routinely using hypotonic salt solutions. The leukocytes 
were then centrifuged (600 g/12 min/4°C) and resuspended in MEM without serum. Cells 
were enumerated using a hemocytometer and viability  determined by trypan blue dye exclusion. 
Wright-Giemsa staining  ofcytocentrifuged PEC from Ca471 cell-immunized  mice revealed 82% 
mononuclear leukocytes (macrophages and lymphocytes), 6% eosinophils, 3% neutrophils, and 
3% mast cells. 
Fractionation of PEC Subpopulations 
GLASS ADHERENT  AND NONAOHEREr~T.  Subpopulations  of C347 l-immune  PEC were separated 
on the basis of adherence to glass. Glass-adherent leukocytes were separated from nonadherent 
cells  by  incubation of  3-4  ×  10  r  PEC  in  100-ram  sterile  glass  petri  dishes  with  MEM 
supplemented with  15-20%  FBS for 2-2.5 h at 37°C in a  humidified atmosphere containing 
5% CO2. Approximately 95% of PEC that adhered to glass in a 6-h incubation adhered in the 
first  2.5 h  after plating. An average of 47%  (+ 5%)  C3471-immune PEC are glass  adherent 
within 2.5 h. Nonadherent PEC were transferred to tubes on ice. The adherent PEC monolayers 
were washed three times each with 5 ml of MEM at 25°C. Adherent PEC were washed twice 
more with ice-cold PBS containing 1 mM EDTA and 1 mM Hepes (Sigma Chemical Co., St. 
Louis, MO). After discarding these fluids, adherent cell monolayers were incubated with cold 
PBS containing EDTA-Hepes for 5-10 rain at 4°C. Adherent PEC were then gently scraped 
using a sterile rubber policeman and transferred to tubes on ice. Both adherent and nonadherent 
PEC were pelleted (600 g/12 min/4°C) and resuspended in MEM without serum for counting 
and viability determinations  as above. Wright-Giemsa staining  of cytocentrifuged preparations 
of glass-adherent immune PEC revealed 97% mononuclear leukocytes, 1% mast cells, and 1% 
neutrophils. Over 95% of these mononuclear  leukocytes were macrophages as measured by their 
capacity to bind and/or ingest glutaraldehyde fixed  erythrocytes coated with IgG (Table I). 
Similar staining of leukocytes in the fraction not adherent to glass revealed 90% mononuclear 
leukocytes,  3% mast cells, and 5% eosinophils. Less than 7% of these leukocytes ingested any 
IgG-coated erythrocytes. 
FRACTIONArtON ON NYLON WOOL.  Nonadherent PEC were further purified for enrichment of 
T  lymphocytes by fractionation on nylon wool columns based on the method of Julius et al. 
(26). Nylon wool from Leuko-Pak Leukocyte Filters (Fenwal Laboratories, Deerfield, IL) was 
soaked  in 0.2 N HCI, boiled in distilled water, and autoclaved. Before addition of leukocytes, 
the columns were washed and preincubated with  PBS containing 5% heat-inactivated FBS 
prewarmed at 37°C. After addition of 0.5-1.5 ×  108 viable glass-nonadherent PEC suspended 
in prewarmed  PBS  +  5%  FBS, columns were  incubated sealed  for  1 h  at  37°C.  PEC  not 
adhering to the nylon wool were eluted dropwise with at least two column volumes of warm 
PBS + 5% FBS into centrifuge tubes, and cell number and viabilities were determined. Wright- 
Giemsa staining of cytocentrifuged nylon wool  eluate cells  revealed a  virtually pure  (98%) 
population of lymphocytes. 
Activation of Adherent PEC In Vitro.  PEC harvested from naive C57BL/6 mice or from ATS- 
treated Cz471-immunized mice were plated on glass petri dishes to separate glass adherent and 
nonadherent fractions as above. Adherent cell monolayers were washed to remove nonadherent 
leukocytes,  and PEC  in the glass-nonadherent or nylon wool-purified fractions from either 
unimmunized  normal C57BL/6 mice or from C3471-immunized  C57BL/6 mice were incubated 
TABLE  I 
Binding and Phagocytosis  of IgG-Coated Erythrocytes by Glass-Adherent  PEC 
Ingested or  Phagocytic Percent  Binding  Percent 
bound particle  index*  control  index*  control 
Resident  IgG-GRBC  442.5 (92):~  100  937.2 (96)~  100 
C3471-immune  IgG-GRBC  738.7 (95)  165  1324.8 (96)  141 
* Phagocytic and binding indices were determined as described previously (3). 
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with the glass-adherent cells for ~ 18 h in MEM containing 10% FBS. At the end of incubation, 
nonadherent PEC were removed and adherent cells were washed with MEM, PBS, and then 
PBS containing 1 mM EDTA and 1 mM Hepes, to minimize contamination with nonadherent 
leukocytes. PEC  still adherent  to the glass petri dishes were then  harvested by scraping, as 
above, counted and coinjected with B559 cells in Winn assays. 
Antisera.  Immune lysis of T  lymphocytes from unfractionated and fractionated PEC was 
carried out using either rabbit ATS having a cytotoxic titer of 1:3,200,  or monoclonal mouse 
anti-Thy-l.2 (gift of Dr. U. Hiimmerling, Memorial Sloan-Kettering Cancer Center) having a 
titer  of  1:10,000.  4-6-wk-old rabbit  complement  obtained  from  Pel-Freez  Biological, Inc. 
(Rogers, AZ) was used at a  1:4 dilution to effect lysis. PEC pellets containing 0.25-2.5 X  107 
viable cells were resuspended in a total volume of no more than 200 ~tl of either rabbit ATS or 
anti-Thy-l.2 in PBS (with Ca  ++ and Mg++), incubated on ice for 30-40 rain, washed in PBS, 
resuspended in 200/~1 PBS containing rabbit complement at 1:4 dilution, and incubated for 20 
min at 37°C in a CO2 incubator. Cell viability was estimated by trypan blue dye exclusion. 
Tumor Neutralization Assay.  A  modification  of  the  adoptive  tumor  neutralization  assay 
described by  Winn  (27)  was  used  to  evaluate  the  effectiveness of immune  peritoneal  cell 
populations in  preventing tumor  formation by  Ba59  melanoma cells. Unfractionated  PEC, 
harvested from naive or immune mice as described above, were washed in PBS and resuspended 
in  MEM  without  serum,  Subpopulations  of immune  PEC  were  similarly  prepared  after 
fractionation. PEC were mixed with freshly harvested B559 cells to give the appropriate PC/ 
B~59 cell ratio in a final volume of 0.2 ml. This cell mixture was inoculated subcutaneously into 
the flank of C57BL/6 mice and animals were checked two to three times weekly for appearance 
of palpable tumor nodules. Tumor formation is reported for all animals used in each experiment. 
In Vitro CytotoxicityAssay.  A colony assay (V. H. Freedman, G. Kaplan, C. S. Copeland, and 
S. C. Silverstein, manuscript in preparation) was used to measure cytotoxicity. Briefly, tumor 
cells were  plated in  16-ram  Costar wells  (Costar,  Data  Packaging, Cambridge,  MA),  and 
overlaid  with  PEC  from  immunized  mice.  After  24  h  incubation,  the  tumor  cells  were 
trypsinized, diluted, and plated in 60-mm petri dishes. Colonies were counted after 7 d. The 
percent B559 cells killed was calculated as number of colonies in experimental sample divided 
by the number of colonies in control sample times 100. 
Results 
Effect of Immunization Route on Rejection of B559 Melanoma.  We compared the efficacy 
of  subcutaneous  vs.  intraperitoneal  immunization  with  Ca471  cells  in  protecting 
C57BL/6 mice against challenge with various numbers of malignant B559 melanoma 
cells. Fig. i shows that at all tumor cell doses tested, mice immunized intraperitoneally 
were  more  resistant  to  intraperitoneal  challenge  with  B559  cells  than  were  mice 
immunized  subcutaneously.  Subcutaneous  immunization  provided  good protection 
against subcutaneous or intraperitonealchallenge only at the lowest tumorigenic dose 
(2 ×  10  .5 B559 ceils). B559 tumors developed in  100% ofunimmunized animals. As will 
become evident, the peritoneal cavities of mice immunized with Ca471  cells contain 
tumoricidal leukocytes. Fig. 1 shows that repeated intraperitoneal immunization with 
C3471  cells was the most efficient method of eliciting these leukocytes. Therefore, all 
subsequent  studies were performed using peritoneal leukocytes elicited by intraperi- 
toneal immunization. 
Effects  of Immunosuppression on  Rejection of B559  Melanoma by  Ca471 Cell-immunized 
Mice.  C57BL/6  mice treated with ATS before inoculation with Ca471  cells develop 
progressive amelanotic Ca471  tumors  (20,  21, 28). To determine whether ATS alters 
established immunity  to  the  malignant  parental  melanoma  (clone B~59),  mice  im- 
munized with C3471  cells were treated with ATS before subcutaneous challenge with 
Bs59  cells.  All  of  these  mice  developed  melanotic  tumors.  In  contrast,  all  of  the 
immunized  control  mice  that  received normal  rabbit  serum  (NRS)  were  protected CALVELLI, FREEDMAN, SILVERSTEIN,  AND SILAGI  1727 
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Fro.  1.  Effect  of immunization route on rejection of subcutaneous vs. intraperitoneal challenge 
with B559 melanoma cells. C57BL/6 mice were immunized by either three subcutaneous (s.c.) or 
intraperitoneal (i.p.) inoculations  of 10  ° Ca471 cells,  each 7 d apart. Immunized mice were challenged 
by either subcutaneous or intraperitoneal injection of the indicated numbers of Bs59 melanoma 
cells, 7 d after the last Ca471 cell inoculation. WI, Unimmunized C57BL/6 control mice challenged 
either i.p. or s.c.; I~, s.c. immunized mice challenge i.p.; m, i.p. immunized mice challenged i.p.; 
s.c. immunized mice challenged s.c.; D, i.p. immunized mice challenge s.c. Mice were monitored 
for tumor formation as described in Materials and Methods. Data represent averages from four 
experiments. 
TABLE II 
Lack of Protection Against Bs59 Melanoma in A TS-treated* Ca4 71-immunized Mice 
Mice injected subcutaneously with 
2 ×  105 B~59 cells 
Mice with 
tumors/mice 
inoculated 
MLP ± SD 
Ca471-immunized 
ATS-treated, Ca471-immunized 
NRS-treated, Ca47  l-immunized 
Unimmunized controls 
0/8 
12/12  9.9 ± 2.1 
0/4 
12/12  12.9 ± 7.6 
* Rabbit  ATS or normal rabbit  serum injected intraperitoneally into C57BL/6 mice immunized with 
Ca471 cells (Materials and Methods). 
against tumor formation (Table II). These results indicate that established immunity 
can be abrogated by ATS treatment; they suggest that ATS-sensitive leukocytes are 
involved in both the afferent and efferent pathways of C3471 cell-elicited host defense. 
To evaluate the radiosensitivity of the cells that mediate B559 tumor cell rejection, 
C57BL/6  mice  were  immunized with  Ca471  cells  and  exposed  to  650  rad  of X 
irradiation 24 h  before inoculation with B559 cells. These mice were unable to reject 
the  B559  ceils  (data  not  shown),  indicating that  radiosensitive effector  cell(s)  are 
required for destruction of B559 cells in C3471 cell-immune mice. 
Characterization of the Leukocytes Elicited by Ca471  Cells.  To confirm that leukocytes 
from  Ca471  cell-immunized mice are responsible for the rejection of B559 cells, we 
mixed varying numbers of Ca471-immune peritoneal leukocytes with 2  X  105  B559 
cells  and  inoculated  them  subcutaneously into  naive C57BL/6  mice.  C3471  cell- 
immune PEC markedly inhibited tumorigenesis by Bs59 cells, completely abrogating 
tumor  formation at  PEC/melanoma  cell  ratios  of 30:1  or  greater,  and  inhibiting 
tumor formation in 90% of mice inoculated with a  25:1  ratio. The latter is therefore 
the ratio of PEC/melanoma cells used for all subsequent Winn assays.  In those few 1728  LEUKOCYTES  ELICITED  BY  NONTUMORIGENIC MELANOMA  VARIANT 
animals that did develop tumors, the mean latent period (MLP)  for development of 
palpable subcutaneous nodules increased progressively as the ratio of PEC/melanoma 
cells  decreased  (Fig.  2).  As  expected,  at  all  ratios  tested  (10:1  to  40:1),  PEC  from 
unimmunized C57BL/6  mice had no inhibitory effect on tumor formation by B559 
cells (data not shown). 
To identify the kinds of leukocytes responsible for the tumoricidal effects of C347 l- 
immune  PEC,  we  carried  out  tumor  neutralization  assays  using  glass-adherent 
(macrophage-enriched)  and  glass-nonadherent  (lymphocyte-enriched)  subpopula- 
tions. 5 ×  10  ~ leukocytes from each subpopulation were as effective in protecting mice 
against  B559  melanoma as unfractionated  immune PEC  (Table III). For those  few 
mice that developed B~59 tumors, the MLP was nearly doubled.  Similar protection 
was obtained when mice were inoculated with a  mixture of 2.5  X  106 each of glass- 
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Fla.  2.  Inhibition ofB559 tumor formation by varying numbers ofC347 l-immune PEC. Peritoneal 
leukocytes,  from mice  immunized by  three  successive  weekly  intraperitoneal  inoculations of  106 
viable  Ca471 ceils,  were co-injected  subcutaneously, in  varying ratios  with  2  X  105  viable  B559 
melanoma cells into immunocompetent na'/ve C57BL/6 mice. Mice were monitored for Bs59 tumor 
formation by palpation of injection sites  two to three times weekly.  Data represent averages from 
seven experiments. 
TABL~  III 
PEC from Ca471 Cell-immunized Mice Inhibit  Tumor Formation by B559 Cells 
Mice with tumors/  MLP +  SD 
C347 l-immune PEC*  mice inoculated  - 
Unfractionated  5/26  20.6 +  15.5 
Glass adherent  4/30  21.0 +  9.9 
Glass nonadherent  6/33  21.3 +_ 6.1 
Glass adherent  +  glass  5/18  18.0 +  9.8 
nonadherent:~ 
Controls§ 
Unfractionated  nor-  29/32  13.7 +  8.4 
real C57BL/6  11/12  11.6 +  4.2 
PEC +  B559 cells 
* PEC  from C3471-immunized  mice  inoculated  in  a  mixture with B~59 melanoma 
cells at a 25:1 ratio using 2 ×  105 viable melanoma cells. 
1: Glass adherent and nonadherent immune PEC  mixed together at a  1:1  ratio after 
separation on glass as described in Materials and Methods. 
§ 2 X  106 B.~59 cells inoculated either alone or together with 5 X  108 PEC from nai've 
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adherent  and  nonadherent  fractions  together  with  B559  cells  (Table  III).  These 
findings differ from those we reported previously using glass-adherent and nonadher- 
ent  fractions  of PEC  elicited  by immunization  with  heat-killed  bacillus  Calmette- 
Guerin  (BCG)  (3)  In those experiments,  only the glass-adherent  leukocytes were able 
to confer protection against B559 tumor formation. 
To characterize the cells in the nonadherent PEC population that were responsible 
for rejection of B559 melanomas,  nonadherent  PEC  from C3471  immune mice were 
treated  with  anti-thymocyte serum  or anti-Thy-l.2  and  complement  and  then  co- 
injected  with  B559 cells  into  naive  mice.  This  treatment  completely  abrogated  the 
capacity of immune nonadherent PEC to protect mice against B559 melanoma (Table 
IV). To confirm that the T  cells alone were capable of inhibiting melanoma formation, 
immune T  cells were purified by passage of C3471-immune nonadherent  PEC over a 
nylon  wool  column.  Mice  inoculated  with  a  mixture  of these  T  cells  and  B559 
melanoma cells were protected against B~59 melanomas; this protection was abolished 
by treatment  of the immune T  cells with anti-thymocyte serum or anti-Thy-l.2 and 
complement (Table IV). In contrast, treatment of C3471 immune glass-adherent PEC 
with  ATS or anti-Thy-l.2  and  complement  had  no effect  on  the  capacity of these 
leukocytes  to inhibit  B559  tumorigenesis  (Table  IV).  These  results  indicate  macro- 
phages  and  thymus-derived  lymphocytes  are  responsible  for  the  in  vivo  tumor 
inhibitory  effects  of the  corresponding  glass-adherent  and  nonadherent  C3471  cell- 
immune  PEC  fractions;  and  that  macrophages  from C3471  immunized  mice retain 
their tumoricidal activity in the absence of immune donor T  cells. 
Participation  of Recipient A TS-sensitive  Leukocytes  in  Rejection  of B559 Melanoma  Cells. 
ATS-sensitive  lymphocytes  can  be  removed  from  either  unfractionated  or  glass- 
adherent  immune  PEC  without  impairing  their  capacity to cause rejection  of B559 
cells  in  Winn  assays  in  normal  mice  (Table  IV).  Therefore,  both  unseparated  and 
adherent  PEC  should  yield  a  high  degree  of protection  if recipient  T  cells  do  not 
TABLE IV 
Effects of In  Vitro Treatment of Ca471-immune PEC With Anti-Thy-l.2 or Rabbit ATS on Their Tumor 
Inhibitory Properties 
Cn471-immune PEC 
subpopulation* 
Treatment 
C' Alone:[:  Anti-Thy-l.2§ + C'  ATS[I + C' 
Mice with  Mice with  Mice with 
Percent  tumors/  Percent tumors/  Percent tumors/ 
lysis  mice inoc-  lysis  mice  inoc-  lysis  mice.inoc- 
ulated¶  ulated¶  ulated~ 
Unfractionated  1.6  0/6  18.8  1/6  20.7  0/8 
Glass adherent  0.9  0/4  3.5  0/5  4.2  1/5 
Glass nonadherent  1.1  0/4  47.1  6/6  49.4  4/4 
Nylon wool nonadherent  0.9  1/21  94.5  8/8  95.3  4/4 
* PEC were obtained and fractionated as described in Materials and Methods. The nylon wool-nonadherent 
cells were obtained by passage of glass-nonadherent cells through nylon wool columns as described in 
Materials and Methods. 
:~ Rabbit complement diluted  1:4. 
§ Monoclonal mouse anti-Thy-l.2  diluted 1:200. 
Jl Rabbit anti-mouse thymocyte serum diluted  1:100. 
¶ PEC inoculated with B559 melanoma cells at 25:1 ratio using 2 ×  105 viable melanoma cells and 5 ×  10  ° 
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participate in the rejection of B559  cells in Winn  assays. To  examine this question, 
naive mice were treated with ATS before inoculation with Ca471  cell-immune PEC 
and  B~59  cells.  ATS  treatment  was  suspended  24  h  before  leukocyte  transfer  to 
minimize  effects  of circulating  anti-T  cell  antibody  on  immune  donor  PEC.  As 
expected, the glass-nonadherent fraction was unable to protect against tumor forma- 
tion  in  the  ATS-treated  recipients.  Surprisingly,  however,  neither  unfractionated 
Ca471-immune  PEC  (containing  macrophages  and  T  cells),  nor  the  glass-adherent 
subfraction  (comprised  primarily of macrophages),  was  able  to  convey  protection 
against  B~59  melanoma  upon  adoptive  transfer  into  ATS-treated  syngeneic  mice 
(Table V). 
The inability of the macrophage-enriched fraction to protect ATS-treated recipients 
against B559 melanoma suggested that recipient T  cells participate in tumor neutral- 
ization by Ca471-immune  macrophages. This  hypothesis is tenable only if the ATS 
used  in  these  experiments  did  not  inhibit  macrophage  recruitment,  viability,  or 
tumoricidal effector functions. Two lines of evidence show that it did not. First, mice 
immunized  intraperitoneally with Ca471  cells for 3  successive wk were treated with 
ATS as described in Materials and Methods. Recovery of total PEC  from these mice 
was  invariably nearly twice that  from  untreated  immune  mice  (7.6  ×  106 vs,  4.5  × 
106), and Wright-Giemsa-stained cytocentrifuge preparations of these PEC contained 
65% macrophages, 2% lymphocytes, 16% neutrophils, and  17% eosinophils. PEC from 
ATS-treated immune  mice  contained  more  macrophages  than  PEC  from  immune 
mice  (4.9 ×  106 vs.  2.25  ×  106).  Second, ATS in the presence  (Table IV) or absence 
of complement  (Tables  VI  and  VII)  did  not  inhibit  the  tumoricidal  activity  of 
immune  macrophages in vitro (Table VI)  or in vivo (Tables IV and VII). That  the 
concentration of ATS used exceeded that in the serum of ATS pretreated mice at the 
time of Winn assay was determined as follows: ATS at a  dilution of 1:100 lysed 95% 
of Ca471-immune  nylon wool-purified T  cells (Table IV), whereas undiluted serum 
from mice treated with ATS (as in Table V)  plus complement lysed only 30-37% of 
these T  cells  (data not  shown).  No  detectable lysis of Ca471-immune  macrophages 
was observed when these cells were incubated with undiluted serum from ATS treated 
TABLE V 
Treatment of Recipient Mice with A TS Blocks the Capacity of C34 71-Immune PEC to Inhibit B559 
Melanoma Formation in Winn Assays 
Untreated recipients~  ATS-treated recipients§ 
C3471-immune  Mice with  Mice with 
subpopulation*  tumors/mice  MLP "4- SD  tumors/mice 
inoculated  inoculated 
MLP + SD 
Unfractionated  0/11  --  14/14  10.4 ± 2.0 
Glass adherent  1/6  19.0 ± 0  7/7  14.5 ±  1.7 
Glass nonadherent  1/7  26.0 ± 0  7/7  15,7 ± 3.8 
B559 Controls  11/11  9.4 ± 2.4  12/12  8.3 ± 3.1 
* As in Table IV. 
Normal C57BL/6 mice. 
§ Normal C57BL/6 mice pretreated with rabbit ATS. These mice received five 0.2-cc inoculations of ATS 
intraperitoneally on days -6, -5, -4, -2, and -  1 before subcutaneous inoculation of immune PEC with 
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TABLE  VI 
A TS Does Not Inhibit Killing ofB559 Melanoma Cells by C34 71-immune 
Adherent PEC In  Vitro 
Number of adherent  ATS:~  Percent B559 cells 
PEC*/well  viable§ 
5 X  106  --  0.01% 
5 ×  106  +  0.01% 
2 ×  106  --  0.5% 
2 ×  106  +  0.5% 
--  -  100% 
--  +  100% 
* Glass-adherent PEC from Cs471-immunized mice harvested as described in 
Materials and Methods. 
:~ ATS at a  1:100 concentration in MEM with 10% FBS. 
§ Percentage  of B559 melanoma cells  killed  is  based  upon  the  number of 
colony-forming units of Bs59 cells remaining after 24 h incubation at 37 ° of 
a mixture of 1 ×  105 B559 cells  and the indicated number of C3471-immune 
PEC.  B559 cells  were harvested and  plated;  colonies were enumerated  as 
described in Materials and Methods. 100% represents the average number of 
B559 colonies recovered from control wells. 
TABLE  VII 
Co-Injection of A TS With Ca471-immune Macrophages Does Not Inhibit  Their Tumoricidal Activity 
Mice with tumors/  MLP "4- SD 
mice inoculated 
C3471-immune adherent PEC*  0/4  -- 
C3471-immune adherent PEC +  ATS~:  0/6  -- 
B559 controls  5/6  16.4 +  3.5 
* Each mouse was inoculated subcutaneously with 0.5  ml MEM containing 5 ×  l0  6 viable glass-adherent 
PEC from Cs471-immunized mice and 2 ×  10  ~ B559 melanoma cells. 
Each mouse was inoculated subcutaneously with 0.2  ml MEM containing 5 ×  106 viable glass-adherent 
PEC  from  Cs471-immunized  mice,  2  ×  105  Bs59  melanoma  cells,  and  2  #1  ATS.  The  final  ATS 
concentration was 1:100. 
TABLE  VIII 
Effect of ATS Treatment In  Vivo on Tumoricidal Activity of PEC of C3471-Immunized Mice* 
Cs47 l-immune 
subpopulation 
Mice with tumors/mice inoculated 
From untreated 
immune donors:~ 
From ATS-treated 
immune donors§ 
From NRS-treated 
immune donorsll 
Unfractionated  2/29  29/30  0/5 
Glass adherent  0/10  14/16  0/8 
Glass nonadherent  0/12  11 / l 2  0/8 
B559 Controls¶  35/36 
* 5 ×  106 PEC harvested from Cs471-immune mice, prepared as described in Materials and Methods, were 
inoculated together with 2 X  105 B559 cells into naive C57BL/6 mice. 
PEC from untreated C3471-immunized mice as in Table IV. 
§ PEC from Ca471-immunized mice as above harvested 24 h after the last inoculation of rabbit ATS. Mice 
were treated with ATS for 3 d  (days -6, -5, and -4) after their last immunization with Ca471 cells, and 
again on the 2 d  (days -2 and -1) before harvest of their PEC as described in Materials and Methods. 
H Mice were treated with NRS following the schedule described above (§). 
¶ 2 ×  105 B559 cells inoculated subcutaneously into naive C57BL/6 mice. 1732  LEUKOCYTES  ELICITED BY  NONTUMORIGENIC MELANOMA VARIANT 
TABLE  IX 
Activation of Macrophage Tumoricidal Activity by Ca4 71-Immune Lymphocytes 
Mice with  Source of glass-adher-  Cells incubated with glass adherent  tumors/mice  MLP +  SD 
ent PEC used in  PEC 
Winn Assays*  inoculated 
ATS-treated, C3471-im-  Glass nonadherent  from  normal  7/7  11.4_ 3.5 
munized  C57BL/6 mice 
Nylon wool eluate from normal  5/5  18.3 +  7.9 
C57BL/6 mice 
Glass  nonadherent  from C3471-  2/21  17.0 +  1.4 
immunized mice 
Nylon wool  eluate  from Ca471-  1/5  26.0 
immunized mice 
Normal C57BL/6 mice  Glass  nonadherent  from normal  3/3  22.3 +  9.8 
C57BL/6 mice 
Nylon wool eluate from  normal  4/4  15.8 +  5.3 
C57BL/6 mice 
Glass  nonadherent  from C3471-  0/5  -- 
immunized mice 
Nylon wool  eluate  from  C3471-  1/4  18.0 
immunized mice 
B~59 cells  None  13/14  12.6 _+ 4.1 
* Glass-adherent  PEC were harvested from either na'ive, untreated C57BL/6 mice or from Ca471-immu- 
nized mice injected intraperitoneally with rabbit ATS after the last inoculation ofC3471  cells and before 
harvest of PEC as in Table VIII and as described  in Materials and Methods. The nonadherent cells were 
incubated  with  the adherent  PEC  for  24  h  and  then  removed by washing,  The adherent  cells were 
removed from the monolayer, mixed with B~59 cells, and inoculated into nai've mice at a ratio of 5 X 106 
viable adherent cells: 2 X 105 B559 cells as described in Materials and Methods. 
mice in the presence of complement  for  1-3 h  at  37°C  (data  not shown). 
A TS-sensitive T  Lymphocytes are Required  for the Maintenance of Tumoricidal Macrophages 
in Ca471 Cell-immune Mice.  To  determine  whether  T  cell  functions  are  required  for 
the  maintenance  of  macrophage  cytotoxic  effector  functions  in  vivo  Ca471  cell- 
immunized  mice  were  treated  with  ATS  after  their  last  immunization  with  C3471 
cells. Their PEC  were then harvested  and  co-inoculated  together with B559 cells into 
na'l've  C57BL/6  mice.  ATS  treatment  of  the  immunized  donor  mice  resulted  in 
abrogation  of  the  tumor  protective  capacity  of  their  PEC;  both  adherent  and 
nonadherent  PEC  were  inactive.  Normal  rabbit  serum  had  no  effect  (Table  VIII). 
These  results  suggested  that  the  inhibitory  action  of ATS  on  the  maintenance  of 
macrophage  tumoricidal activity was an indirect one, a consequence of ATS-mediated 
destruction  of T  lymphocytes.  If so,  then  addition  of C3471-immune  lymphocytes  to 
these  macrophages  should  restore  their  tumoricidal  activity.  To  test  this  hypothesis, 
glass-adherent  PEC  harvested  from  ATS  treated  immune  mice,  were  washed  to 
remove nonadherent  leukocytes,  and  incubated  for  18  h  with  nonadherent  or nylon 
wool-purified  leukocytes  from  Ca471-immunized  donors  or  from  nonimmunized 
C57BL/6  mice.  Nonadherent  PEC  were  removed  by  extensive washing.  92%  of the 
glass-adherent  cells  ingested  IgG-coated  glutaraldehyde-fixed  sheep  erythrocytes, 
showing  that  the  washing  procedure  was  sufficient  to  remove  virtually  all  added 
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B559 melanoma cells into naive C57BL/6 mice. Macrophages incubated with either 
glass nonadherent or nylon wool-purified leukocytes from immunocompetent C3471- 
immune mice, conferred a high degree of protection against B559 tumor formation to 
naive Winn assay recipients (Table IX). Macrophages incubated with either nonad- 
herent or nylon wool-purified cells from unimmunized C57BL/6 mice provided no 
protection against  tumor formation (Table IX).  These results confirm that  T  lym- 
phocytes from C3471-immune mice are essential for the generation and maintenance 
of the tumor inhibitory properties of macrophages. 
To determine whether lyrnphocytes from C3471  cell-immune animals could stimu- 
late macrophage turnoricidal activity in the absence of tumor antigens in the adherent 
cell  population,  macrophages  from  normal,  nonimmunized  C57BL/6  mice  were 
incubated with glass nonadherent or nylon wool eluate PEC from C~471-immunized 
mice. At the end of the incubation, the nonadherent cells were removed by extensive 
washing.  (Over  90%  of the  remaining  adherent  leukocytes  were  macrophages  as 
measured by their ingestion  of IgG-coated glutaraldehyde-fixed erythrocytes [IgG- 
GRBC].) The adherent leukocytes were detached from the plates and coinjected with 
B559 melanoma cells into na'ive mice. These adherent cells prevented tumor formation 
in eight of nine recipients (Table IX). All animals receiving macrophages that had 
been incubated with glass nonadherent or nylon wool eluate cells from unimmunized 
mice developed lethal melanomas (Table IX). 
Acquisition of Tumor Immunity by Winn Assay Recipients.  B559 melanoma cells are not 
immunogenic. B559 tumor formation is not prevented by inoculation of mitomycin- 
treated  or  radiation-killed  B559  cells  (I,  29),  or  by repeated  inoculation  of crude 
membranes prepared from cultured B~59 cells (29) into syngeneic mice. Also, animals 
bearing  B659  tumors  do  not  exhibit  concomitant  tumor  immunity  (3).  Efforts to 
transfer  immunity  against  B~59  melanoma  to  naive  syngeneic  mice  with  C3471- 
immune leukocytes have been unsuccessful. Neither 107 peritoneal nor 107 spleen cells 
from Cn471-immunized mice conferred any protection against B559 tumor formation 
even when administered on multiple occasions, subcutaneously, or intravenously to 
normal or sublethally irradiated naive C57BL/6 mice. In these experiments 27 of 28 
normal  mice  and  22  of  23  irradiated  mice  receiving  C3471-immune  leukocytes 
developed lethal melanomas when challenged with 2 ×  105 B~59 cells. However, when 
animals that had received 5 ×  10  ° unfractionated C3471-immune PEC together with 
the melanoma cells in a Winn assay were tested by a second injection of B~59 cells 40- 
60 d later,  12 of 21 animals remained free of tumors 40 d after this second challenge. 
Thus, a significant degree of systemic immunity to B559 melanoma can be adoptively 
transferred by immune peritoneal leukocytes in the presence of tumor cells. 
Discussion 
We have examined the mechanism of rejection of clone B559 of B 16 melanoma by 
syngeneic C57BL/6 mice immunized with an immunogenic variant (clone Ca471) of 
the parental melanoma. Immunization with C3471 cells results in systemic immunity 
to B~59 melanoma (1, 2). The protective effect of immunization is most pronounced 
when immunization and subsequent challenge are within the same tissue compart- 
ment  (the  peritoneal  cavity);  nonetheless,  significant  systemic resistance  to  tumor 
challenge  is  observed when  the  sites  of immunization  and/or  tumor  challenge lie 
outside  the peritoneum  (Fig.  1).  Treatment of na'ive mice with ATS before C3471 1734  LEUKOCYTES  ELICITED BY NONTUMORIGENIC  MELANOMA VARIANT 
inoculation permits the development of C3471  tumors (20), and established immunity 
to B559 cells can be abrogated by ATS treatment  (Tables II and V) or X  irradiation 
of the immune mice. These findings indicate that intact T  cell function is required for 
the establishment  and maintenance of immunity to this melanoma. This conclusion 
was substantiated when leukocyte subpopulations from immune mice were coinjected 
with B~59 cells into naive or ATS-treated recipients. Macrophage or T  cell enriched 
populations  prevented  tumor  growth  in  naive  mice but  not  in  ATS-treated  mice 
(Table V). 
There are two distinct pathways via which immune T  cells might act in this system. 
T  cells might function as cytotoxic effector cells or as amplifier and helper cells. We 
do not know whether C3471-immune T  cells are themselves cytotoxic. Further work 
is needed to resolve this issue. However, our data do indicate that these T  cells act as 
amplifiers of the immune reaction, promoting the activation of mononuclear phago- 
cytes that are tumoricidal in vivo (Table IX). A requirement for cooperation between 
mononuclear phagocytes and immune T  cells is further emphasized by the inability 
of macrophages from C3471-immunized mice to prevent tumors in ATS-treated Winn 
assay recipients (Table V). 
Previous work with macrophages elicited by BCG immunization showed that co- 
injection of BCG-activated macrophages together with Bg59 cells inhibited melanoma 
formation in normal, X-irradiated and nude mice (3).  Thus it was surprising to find 
that demonstrably tumoricidal macrophages from C3471-immune mice did not inhibit 
B~59 melanoma formation in mice treated with ATS (Table V). Careful examination 
of the effects of ATS showed that this serum did not inhibit macrophage recruitment 
in vivo, or macrophage viability or tumoricidal activity in vitro (Tables IV, VI, and 
VII).  These  findings  indicate  that  the  inhibitory  effect  of  ATS  on  macrophage 
tumoricidal  activity  in  vivo  is  not  due  to  a  direct  action  of  this  serum  on  the 
macrophages. We conclude that T  cell functions are required  for the full expression 
of macrophage tumoricidal activity in vivo. 
In addition to a requirement for T  cells and macrophages, other cell types may be 
involved  in  the  rejection  of Bg59  cells  by Cz471  cell-immunized  mice.  Beige  mice 
immunized with C3471  cells fail to reject B559 melanoma (38), suggesting that natural 
killer and/or other leukocyte subpopulations that are defective in beige mice (39-41) 
may be required. 
Approximately half of the animals that reject B559 cells after co-injection of these 
melanoma cells with immune PEC developed long lasting immunity to B559 cells as 
measured by their ability to reject a challenge with the tumorigenic melanoma cells. 
In contrast, as we reported previously (3), mice that did not develop tumors after co- 
injection  of BCG-immune PEC  with  B559  cells remained completely susceptible to 
subsequent  challenge  with  B559  cells.  Thus,  the  ability  of the  mice  that  received 
C3471-immune  peritoneal  leukocytes  and  B~59  melanoma  cells  to  resist  a  second 
challenge 40-60 d  later appears to be due to stimulatory effects on the host immune 
system of adoptively transferred immune leucocytes in the presence of antigen  (B~59 
cells). 
The BrdUrd-induced  changes responsible for the immunizing properties of Ca471 
cells have not been defined.  However, virus production by C3471  cells seems to play 
a key role. C57BL/6 mice immunized with nontumorigenic feral mouse cells chroni- 
cally infected with C3471  cell-derived retrovirus are protected against challenge with CALVELLI, FREEDMAN, SILVERSTEIN, AND SILAGI  1735 
B559 melanoma cells (38). 
In summary, three novel findings emerge from this work. First, that  an intact T 
lymphocyte system is needed to elicit tumoricidal macrophages by immunization with 
the nontumorigenic BrdUrd-grown melanoma variant. Second, that the tumoricidal 
macrophages elicited are unable to mediate rejection of B559  melanoma cells in  a 
Winn assay in the absence of intact recipient T  lymphocyte function, further empha- 
sizing  a  requirement  for cooperation of T  cells with  other  leukocyte populations. 
Third, that a significant proportion of nai've C57BL/6 mice can be immunized against 
B559  melanoma  when  these  tumor cells are  co-injected with  peritoneal cells  from 
C3471  cell-immune mice. This last  finding suggests one approach to immunization 
against nonimmunogenic syngeneic tumors. 
Summary 
The mechanisms by which various leukocyte subpopulations elicited by an immu- 
nogenic, nontumorigenic subclone (Cz471) of B16 melanoma caused rejection of the 
tumorigenic parental  melanoma  (B559),  were investigated.  Leukocytes from C3471- 
immune  mice were co-injected with  B559  tumor cells  in  Winn  assays  into normal 
syngeneic recipients.  Tumor  formation  by  Bs59  cells  was  prevented when  C3471- 
immune (a) unfractionated peritoneal leukocytes, or (b) glass-adherent peritoneal cells 
(90% macrophages), or (c) nylon wool purified nonadherent cells (95% Thy-1.2  +) were 
used  in  the Winn  assays.  If the C3471-immunized mice were treated with antithy- 
mocyte serum before harvest of their peritoneal cells, none of these leukocyte popu- 
lations were effective in the Winn assay.  However, macrophages from these immu- 
nologically compromised donors regained their tumoricidal activity after incubation 
in vitro with T  lymphocytes from untreated Cz471-immune donors; similarly, C3471- 
immune lymphocytes rendered normal resident peritoneal macrophages tumoricidal 
in  Winn  assays.  When  C3471-immunized  mice  were  irradiated  or  treated  with 
antithymocyte serum before direct challenge with B559 cells, melanomas developed, 
thus providing additional evidence for the need for intanct T cell function to establish 
immunity  against  the  melanoma.  Furthermore, when  Winn  assay  recipients were 
treated with antithymocyte serum, neither C3471-immune macrophages nor T  cells 
were able to prevent tumor formation. These findings indicate that  antithymocyte 
serum-sensitive  (Thy-l.2  +)  lymphocytes  are  necessary  both  for  the  generation  of 
tumoricidal  leukocytes  in  C3471-immunized  mice,  and  for  the  rejection  of B559 
melanoma by demonstrably tumoricidal macrophages in Winn assay recipients. In 
addition,  long-lasting  immunity  developed  in  50%  of the  normal  mice  that  had 
received both C3471-immune peritoneal cells and B~59 tumor cells, as manifested by 
their capacity to reject a second challenge with B559 cells 40-60 d later. 
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